SCLERO.ORG is retiring 4-24-2021. Thank you for the memories! You'll still find us in the Wayback Machine, and we'll carry your stories in our hearts forever.
Scleroderma Newsroom
ISN News Manager: Jo Frowde
Media Stories
Scleroderma Archive
We maintain news archives for the most recent 3 years.
2020: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2021 - 2020 - 2019 - 2018

October 2020 Scleroderma News

Recognising the spectrum of scleromyositis: HEp-2 ANA patterns allow identification of a novel clinical subset with anti-SMN autoantibodies. Using HEp-2 IIF patterns, three novel clinicoserological subsets of scleromyositis emerged. PubMed, RMD Open, 2020 Sep;6(2):e001357. (Also see Myopathy and Myositis)

Effects of Sense and Functionality Changes in the Hands on Activity and Participation in Patients with Juvenile Scleroderma. Sensory and functional disorders caused by hand involvement in JS patients result in limitation of daily living activities and affect negatively the effective usage of the hand. PubMed, Mod Rheumatol, 2020 Aug 28;1-25. (Also see Juvenile Scleroderma Research)

The incidence rate of pulmonary arterial hypertension (PAH) and scleroderma renal crisis (SRC) in systemic sclerosis patients with digital ulcers on endothelin antagonist receptors (ERAs) and phosphodiesterase-5 inhibitors (PDE5i). Treatment with ERAs and/or PDE5i appeared to delay the occurrence of SRC. PubMed, Rheumatology (Oxford), 2020 Aug 26;keaa401. (Also see Pulmonary Hypertension, Kidney (Renal) Involvement and Research on Digital Ulcers)

Frontiers in translational systemic sclerosis (SSc) research: a focus on the unmet 'cutaneous' clinical needs (Viewpoint). This viewpoint considers four cutaneous unmet clinical needs of patients with Ssc, which cause pain, disability, and/or disfigurement, all impact on quality of life, and for each we require effective treatments. PubMed, Exp Dermatol, 08/25/2020. (Also see Skin Involvement)

Worsening of esophageal dilatation is associated with increase in a high-resolution computed tomography (HRCT) score in early systemic sclerosis-associated interstitial lung disease (Ssc-ILD). Our study cohort found that a worsening esophageal diameter was a predictor of progression of lung fibrosis determined by HRCT score in early SSc-ILD. PubMed, Clin Rheumatol, 08/15/2020. (Also see Correlation between Pulmonary Fibrosis and other Diseases or Complications and Gastrointestinal Involvement)

Translational engagement of lysophosphatidic acid receptor 1 (LPA1) in skin fibrosis: from dermal fibroblasts of patients with scleroderma to tight skin 1 mouse. Our results support the therapeutic potential of LPA1 receptor antagonists in systemic sclerosis. PMC, Br J Pharmacol, 2020 Sep; 177(18): 4296–4309. (Also see Skin Fibrosis and Fibroblasts)

The Role of Fecal Calprotectin in Patients with Systemic Sclerosis (SSc) and Small Intestinal Bacterial Overgrowth (SIBO). The development of SIBO in SSc patients, when associated with intense gastrointestinal symptoms and frequent diarrhoea often leads to malabsorption and malnutrition. PMC, Diagnostics (Basel), 2020 Aug; 10(8): 587. (Also see Bowel Dysfunction)

Lenabasum Fails to Show Efficacy in Diffuse Cutaneous Scleroderma (dcSSc), Phase 3 Trial Shows. Treatment with lenabasum failed to outperform a placebo when given as an add-on to standard immunosuppressants in adults with dcSSc, top-line data from a Phase 3 trial show. Scleroderma News, 09/09/2020. (Also see Clinical Trials)

Gastric Juice Expression of Th-17 and T-Reg Related Cytokines in Scleroderma Esophageal Involvement. This is the first report of cytokines measurement in gastric juice of patients with SSc. PubMed, Cells, 2020 Sep 16;9(9):E2106. (Also see Esophageal (Throat) Involvement and Cytokines)

Machine learning predicts stem cell transplant (HSCT) response in severe scleroderma (SSc). This study suggests that intrinsic subset stratification of patients may be used to identify patients with SSc who receive significant benefit from HSCT. PubMed, Ann Rheum Dis, 2020 Sep 15;annrheumdis-2020-217033. (Also see Stem Cell Transplantation)

Go to Scleroderma Medical News: September 2020

SCLERO.ORG was the world's leading nonprofit for trustworthy research, support, education and awareness for scleroderma and related illnesses from 1998 to 2021. It was a grassroots movement from the original Scleroderma from A to Z web site, which was founded by Shelley Ensz. We were a 501(c)(3) U.S.-based public charitable foundation. We closed this web site and our nonprofit agency in April 2021.

International Scleroderma Network (ISN)